Clinical Laserthermia Systems publishes annual report for 2024
6 juni, 21:00
6 juni, 21:00
Clinical Laserthermia Systems publishes annual report for 2024
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the company”) today published its annual report for fiscal year 2024.
Clinical Laserthermia Systems AB (publ) (“CLS” or “the company”) today published its annual report for fiscal year 2024. The report is available in Swedish on the company’s website https://clinicallaser.se/. It is also attached to this press release.
Contact information:
Dan J. Mogren, CEO Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)705 – 90 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG® Thermal Therapy System and ClearPoint Prism® Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se
6 juni, 21:00
Clinical Laserthermia Systems publishes annual report for 2024
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the company”) today published its annual report for fiscal year 2024.
Clinical Laserthermia Systems AB (publ) (“CLS” or “the company”) today published its annual report for fiscal year 2024. The report is available in Swedish on the company’s website https://clinicallaser.se/. It is also attached to this press release.
Contact information:
Dan J. Mogren, CEO Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)705 – 90 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG® Thermal Therapy System and ClearPoint Prism® Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se
Analys
Danmarks nationaldag
Fondernas placeringar
Inflationen
Investmentbolag
Analys
Danmarks nationaldag
Fondernas placeringar
Inflationen
Investmentbolag
1 DAG %
Senast
Novo Nordisk
5 juni, 16:36
Nordeas miljonärer köper danskt
OMX Stockholm 30
1 DAG %
Senast
2 521,51